Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis
- First Online:
- 167 Downloads
A period of tumor growth precedes the clinical detection of breast cancer recurrence. We explore immune, endocrine, and behavioral parameters during this period.
We conducted a phase III clinical trial in which women with surgically treated stage II/III breast cancer (N = 227) were randomized to receive a psychological intervention or assessment-only and then regularly assessed for 10 years. Patients who recurred (R, n = 48) were matched with patients remaining disease-free (DF, n = 48) on demographic and prognostic characteristics, treatment, and duration of disease-free follow-up. Data at three assessment points, occurring, on average, 17, 11, and 4 months before the recurrence was detected clinically, with equivalent time points for the disease-free group, were examined. Mixed-effects models tested for group differences in immune cell counts and function as well as endocrine and behavioral parameters.
In the 17 months prior to recurrence detection, patients exhibited higher white blood cell count, neutrophil, lymphocyte, and natural killer cell counts, relative to DF patients. R patients also showed higher cortisol, worse physical functioning, fatigue, and quality of life. Follow-up analyses showed patients with local recurrences to differ from those with distant recurrence, with the former exhibiting elevated natural killer cell cytotoxicity, lymphocyte proliferative response, fatigue, pain, and emotional distress (depression, anxiety), and the latter exhibiting higher neutrophil, lymphocyte, and natural killer cell counts.
Patients who would recur showed reliable biobehavioral alterations more than a year prior to their diagnosis. This novel observation may contribute to our understanding of the disease relapse processes.
KeywordsBreast neoplasms Neoplasm metastasis Leukocytes Granulocytes Fatigue Inflammation
- 1.SPSS 14.0 for Windows. Release 14.0.0. SPSS, Inc, ChicagoGoogle Scholar
- 2.American Joint Committee on Cancer (1997) AJCC cancer staging manual. Lippincott-Raven, PhiladelphiaGoogle Scholar
- 3.American Joint Committee on Cancer (2002) AJCC cancer staging manual. In: Greene FL (ed). Springer, New YorkGoogle Scholar
- 18.Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 199–205Google Scholar
- 19.Kee JL (2005) Laboratory and diagnostic tests. Pearson Education, Upper Saddle RiverGoogle Scholar
- 21.Levy SM, Wise BD (1987) Psychosocial risk factors, natural immunity, and cancer progression: Implications for intervention. Health Psychol 6(3):229–43Google Scholar
- 22.McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood states. Educational and Industrial Testing Service, San DiegoGoogle Scholar
- 25.Nagtegaal ID, Marijnen CA, Kranenbarg EK et al (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect—a histopathological and immunohistochemical study. BMC Cancer 1:7PubMedCrossRefGoogle Scholar
- 26.Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 49(22):6443–6444Google Scholar
- 34.Ware JE, Snow KK, Kosinski M (2000) SF-36 health survey: manual and interpretation guide. QualityMetric Incorporated, LincolnGoogle Scholar